Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMELEON: lazertinib with or without chemotherapy based on ctDNA clearance in EGFR-mutant NSCLC
KCT0008774Phase 2Recruiting
- Sponsor
- Yuhan
- Start
- Aug 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lazertinib, carboplatin, pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Yuhan. Started Aug 2024; status: recruiting.
02
Drugs
lazertinibcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0008774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008774.